➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Johnson and Johnson
Dow
Baxter
Mallinckrodt

Last Updated: September 23, 2020

DrugPatentWatch Database Preview

Patent: 8,946,387

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,946,387
Title:Fc.gamma.RIIB specific antibodies and methods of use thereof
Abstract: The present invention relates to antibodies or fragments thereof that specifically bind Fc.gamma.RIIB, particularly human Fc.gamma.RIIB, more particularly the extracellular domain of Fc.gamma.RIIB with greater affinity than said antibodies or fragments thereof bind Fc.gamma.RIIA, particularly human Fc.gamma.RIIA, and block the Fc binding site of Fc.gamma.RIIB. The present invention also encompasses the use of an anti-Fc.gamma.RIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin\'s lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The present invention also encompasses the use of an anti-Fc.gamma.RIIB antibody or an antigen-binding fragment thereof, in combination with other cancer therapies. The present invention provides pharmaceutical compositions comprising an anti-Fc.gamma.RIIB antibody or an antigen-binding fragment thereof, in amounts effective to prevent, treat, manage, or ameliorate a cancer, such as a B-cell malignancy, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention further provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention with a vaccine composition. The invention further provides methods of treating cancer and/or regulating immune complex-mediated cell activation by administering the antibodies of the invention to enhance an immune response. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention.
Inventor(s): Koenig; Scott (Rockville, MD), Veri; Maria Concetta (Denwood, MD), Tuaillon; Nadine (Gettysburg, PA), Bonvini; Ezio (Rockville, MD)
Assignee: MacroGenics, Inc. (Rockville, MD)
Application Number:12/186,065
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,946,387
Patent Claims:see list of patent claims

Details for Patent 8,946,387

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech XOLAIR omalizumab VIAL 103976 001 2003-06-20   Start Trial MacroGenics, Inc. (Rockville, MD) 2022-08-14 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Baxter
Boehringer Ingelheim
Johnson and Johnson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.